This work is licensed under a Table 1.
Baseline demographics and clinical characteristics (stratified by previous SSA use)
| Characteristic | SSA naïve (n=41) | Previous SSA (n=155) | All patients (n=196) |
|---|---|---|---|
| Median age (range), years | 59 (37–75) | 60 (27–81) | 60 (27–81) |
| Sex, n (%) | |||
| Male | 22 (54) | 92 (59) | 114 (58) |
| Female | 19 (46) | 63 (41) | 82 (42) |
| WHO PS, n (%)a | |||
| 0 | 30 (73) | 100 (65) | 130 (66) |
| 1 | 11 (27) | 45 (29) | 56 (29) |
| 2 | 0 | 10 (6) | 10 (5) |
| Tumor location, n (%)b | |||
| Foregut | 15 (37) | 17 (11) | 32 (16) |
| Midgut | 24 (59) | 119 (77) | 143 (73) |
| Hindgut | 2 (5) | 19 (12) | 21 (11) |
| Histology, n (%)c | |||
| Well differentiated or low-grade | 32 (78) | 128 (83) | 160 (82) |
| Moderately differentiated or intermediate-grade | 9 (22) | 20 (13) | 29 (15) |
| Poorly differentiated or high-grade | 0 | 1 (<1) | 1 (<1) |
| Unknown | 0 | 6 (4) | 6 (3) |
| Time since initial diagnosis, n (%)d | |||
| ≤6 months | 10 (24) | 11 (7) | 21 (11) |
| >6 months–≤2 years | 9 (22) | 37 (24) | 46 (23) |
| >2–≤5 years | 14 (34) | 35 (23) | 49 (25) |
| >5–≤10 years | 6 (15) | 51 (33) | 57 (29) |
| >10 years | 2 (5) | 20 (13) | 22 (11) |
| Systemic antitumor drugs, n (%) | |||
| Chemotherapy | 11 (27) | 43 (28) | 54 (28) |
| Immunotherapy | 1 (2) | 18 (12) | 19 (10) |
| Targeted therapy | 1 (2) | 13 (8) | 14 (7) |
| Other | 1 (2) | 25 (16) | 26 (13) |
| Previous SSA therapy, n (%) | |||
| Octreotide LAR | – | 142 (92) | 142 (72)e |
| Lanreotide | – | 13 (8) | 13 (7)e |
WHO PS, World Health Organization performance status; SSA, somatostatin analogues; LAR, long-acting repeatable.
Data missing for one patient.
Tumors originating in the lung, stomach, duodenum, or pancreas were categorized as foregut NET; those originating in the small intestine, appendix, proximal colon, or of unknown primary sites were considered to be midgut NET; and those with the colon (transverse or distal) or rectum as the primary site were classified as hindgut NET.
The histology-based categories as reported in pathology reports. At the time of study conduct, the harmonized definition of grading for NET was not established and the WHO classification was not in practice. Thus, the categories reported here may not translate in to strict numerical categories based on WHO grading (based on mitotic count and/or Ki-67 labeling index) being used in current clinical practice.
Data missing for two patients.
Total is not 100%, as 41 (21%) patients did not receive prior SSA therapy.